Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
ASH 2015
ASH 2015 – Castleman's Disease, Lymphoma, and CLL
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
R-CHOP ± Bortezomib in Patients with Untreated Non-GCB DLBCL: Results from the Phase 2 PYRAMID Trial
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Lenalidomide Maintenance in Patients with Relapsed DLBCL Who Cannot Be Treated with Consolidative Transplantation
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Addition of Obinutuzumab or Rituximab to Chlorambucil in Treatment-Naive Patients with CLL: Updated Survival Analysis from the CLL11 Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Impact of High-Risk Prognostic Parameters on Ibrutinib/Bendamustine/Rituximab versus Bendamustine/Rituximab Treatment Outcomes in Patients with Relapsed CLL/SLL: Results from the HELIOS Trial
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Health-Related Quality-of-Life Assessment of Obinutuzumab plus Bendamustine versus Bendamustine in Patients with Rituximab-Refractory Indolent NHL: Results of the GADOLIN Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Effect of Ibrutinib versus Temsirolimus Treatment on Lymphoma Symptoms in Patients with Previously Treated Mantle-Cell Lymphoma (MCL): Results of the RAY (MCL3001) Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Management of Adverse Events in the HELIOS Trial in Patients with Previously Treated CLL/SLL
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Abexinostat in Patients with NHL and CLL: Results of an Ongoing Phase 2 Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Relapsed/Refractory NHL
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Venetoclax (ABT-199/GDC-0199) plus Bendamustine/Rituximab in Relapsed/Refractory NHL: Results of a Dose-Escalation Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Addressing Cancer Health Disparities: The No One Left Alone Initiative
Rohan Nathwani
,
Arva Patel
,
Warner Kornberg
,
Asutosh Gor, MD
,
Sashi Naidu, MD
,
Viral Rabara, MD
,
Niyati Nathwani, MD
,
Kashyap Patel, MD
2.
Navigating the Complex Landscape of Oral Cancer Medication
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma